Duane Peters from the Lupus Foundation of America interviews Dr Diane Apostolopoulos and Dr Eric Morand from Monash Health in Australia about their study into the prevalence of metabolic syndrome in patients with SLE and the potential associations between the use of glucocorticoids and specific cardiovascular risk factors. Access the paper here: https://lupus.bmj.com/content/7/1/e000436

Lupus Science and Medicine podcast

Metabolic syndrome in SLE patients

Duane Peters from the Lupus Foundation of America interviews Dr Manuel Francisco Ugarte-Gil from Peru and Dr Joan Merrill and Dr Anca Askanase from the USA about their study evaluating the use of LFA-REAL clinician-reported and patient-reported outcomes in establishing disease severity in SLE. Access the paper here: https://lupus.bmj.com/content/7/1/e000419

Validating the use of LFA-REAL to measure disease severity in SLE

Duane Peters from the Lupus Foundation of America interviews Dr May Choi and Dr Peter Schur from the Lupus Program at Brigham and Women's Hospital in Boston. They discuss the use of the ANA assay for the diagnosis and classification of systemic lupus and other autoimmune rheumatic diseases. Access the paper here: https://lupus.bmj.com/content/7/1/e000431

ANA testing in SLE and autoimmune rheumatic diseases

Duane Peters of the Lupus Foundation of America talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper: Kynurenine pathway is altered in patients with SLE and associated with severe fatigue. Access the paper here: http://doi.org/10.1136/lupus-2017-000254

Kynurenine pathway is altered in patients with SLE and associated with severe fatigue

Senior Communications Strategist at the Lupus Foundation Duane Peters talks to Elisabet Svenungsson and Helena Idborg from Karolinska Institutet about their published paper:TNF-alpha and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus. Access the paper here: http://doi.org/10.1136/lupus-2018-000260

TNF-α and plasma albumin as biomarkers of disease activity in systemic lupus erythematosus

Duane Peters from the Lupus Foundation of America interviews Dr Jill Buyon, Professor of Rheumatology at New York University School of Medicine and co-Editor-in-Chief of Lupus Science & Medicine. Dr Buyon presents an overview of the journal's strengths and unique features, the editorial review process, and why authors should consider submitting their next lupus paper to LSM. Learn more about the journal at lupus.bmj.com

Lupus Science & Medicine: what makes it special?

Lupus Science & Medicine Associate Editor Professor Lars Ronnblom talks to Professor Joan T. Merrill from the Oklahoma Medical Research Foundation about her published paper: Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus. Access the paper here: https://lupus.bmj.com/content/5/1/e000284

Anifrolumab effects on rash and arthritis

Dr Jill Buyon, co-Editor in Chief of Lupus, Science & Medicine, explores the lessons we're learning six months into the global pandemic and the impact this is having on lupus patients, the medical landscape, and the research publishing space.

COVID-19 Impact on people with lupus

In the second part of a general update on the effects of Covid-19 in lupus patients, Sara Booth, University of Cambridge, talks to Dr Anca D Askanase, MD, MPH Director, Columbia University Lupus Center Associate Professor of Medicine Columbia University College of Physicians and Surgeons. Listen to part one on your favourite podcast provider, including one of the links below: https://soundcloud.com/bmjpodcasts/immunity-for-lupus-patients-and-effects-of-covid-19-part-1 Apple Podcasts: https://podcasts.apple.com/gb/podcast/lupus-science-and-medicine-podcast/id1023734925 Google Podcasts: https://podcasts.google.com/?feed=aHR0cDovL2ZlZWRzLmJtai5jb20vbHVwdXMvcG9kY2FzdHM&hl=en-GB

Lupus, immunity and Covid-19 - Part 2

In this podcast, Sara Booth, University of Cambridge, talks to Professor Sarah Rowlands (Florey Professor of Infection and Immunity,University of Sheffield and Honorary Consultant Physician Nuffield Department of Medicine, Oxford), who specialises in infectious diseases and has a special interest in immunity to viruses. Listen to part two on your favourite podcast provider, including one of the links below: https://soundcloud.com/bmjpodcasts/lupus-immunity-and-covid-19-part-2 Apple Podcasts: https://podcasts.apple.com/gb/podcast/lupus-science-and-medicine-podcast/id1023734925 Google Podcasts: https://podcasts.google.com/?feed=aHR0cDovL2ZlZWRzLmJtai5jb20vbHVwdXMvcG9kY2FzdHM&hl=en-GB

Immunity for lupus patients and effects of Covid-19 - Part 1

An insight into the important learnings of the Lupus Academy 2017 is brought to you in this special Lupus Science & Medicine podcast. The Editor-in-Chief of the journal Ronald van Vollenhoven, a founding member of the Lupus Academy, spoke with several of the faculty and the delegates during the meeting held in Lisbon, Portugal, between the 5th and the 7th of May. The Lupus Academy is a UK-based not-for-profit organisation dedicated to providing high-quality education to medical specialists and trainees regarding Systemic lupus erythematosus (SLE). The 5th annual conference was attended by around 140 delegates from many different, mostly European countries, and the large international faculty produced an educational program. Highlights of the meeting include a debate session on the topic of "Mixed connective tissue disease - is the term archaic and should it be abandoned" where the side in favor of this proposal won a narrow victory; plenary lectures on a wide range of topics from the immunopathology of SLE to the latest in treatment; case discussion workshops on selected features of SLE; and "breakfast with the professor" sessions for informal discussions with the faculty. Ronald van Vollenhoven talked to: • Professor Roger Levy (The State University of Rio de Janeiro, Brazil); • Professor Sandra Navarra (University of Santo Tomas, Manila, Philippines); • Professor Anisur Rahman (University College London, London, UK); • Professor Andrea Doria (Padova University School of Medicine, Italy); • Sara Badreh (Lupus Europe) representing the patients from 24 European countries. Please visit the Lupus Science & Medicine website: http://lupus.bmj.com/.

Education and the latest in treatment: reporting from the Lupus Academy 2017

To mark the first anniversary of Lupus Science and Medicine Harriet Vickers speaks to Dr Ronald van Vollenhoven and Dr Jill Buyon about notable published papers, publishing without an impact factor and what to expect from the journal in the coming year.

Lupus Science and Medicine first year anniversary

Sandra Raymond, president and CEO of the Lupus Foundation of America, talks about why the foundation wanted to create Lupus Science and Medicine, and what she hopes the journal will achieve.For more information on the journal, see http://journals.bmj.com/site/lupus/index.html.

BMJ and the Lupus Foundation of America announce the first open access lupus scientific journal

The Lupus Foundation of America and BMJ are joining forces to publish Lupus Science and Medicine, the first open access lupus scientific journal.Joint editor-in-chief Ronald van Vollenhoven, also head of the Unit for Clinical Therapy Research, Inflammatory Diseases, Karolinska Institutet, discusses what readers and authors can expect from the journal.To sign up for updates about the journal, go to: http://journals.bmj.com/site/lupus/index.html

What to expect from Lupus Science and Medicine

Lupus Science and Medicine is a global, peer reviewed, Open Access, online journal that provides a central point for publication of basic, clinical, translational, and epidemiological studies of all aspects of lupus and related diseases. It is the first lupus-specific Open Access journal in the world and was developed in response to the need for a barrier-free forum for publication of groundbreaking studies in lupus. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

hubhopper

Lupus Science and Medicine podcast

hubhopper